Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 chronic lung disorders. They are characterized by inflammation and scarring of the lung interstitium, leading to progressive dyspnea and impaired gas exchange. This article provides a comprehensive overview of ILDs, focusing on etiology, clinical features, diagnostic approaches, and treatment strategies.
ILDs can be classified based on their etiology into idiopathic, occupational, drug-induced, and those associated with systemic diseases. The most common form is idiopathic pulmonary fibrosis (IPF), the cause of which remains unknown. Occupational and drug-induced ILDs are caused by exposure to harmful substances or certain medications respectively, while systemic diseases like rheumatoid arthritis or scleroderma may also involve the lung interstitium.
Patients with ILDs typically present with chronic, progressive dyspnea and non-productive cough. Physical examination may reveal bibasilar inspiratory crackles and finger clubbing. Advanced stages may manifest with signs of right heart failure due to pulmonary hypertension.
High-resolution computed tomography (HRCT) is the cornerstone of ILD diagnosis, showing characteristic patterns like honeycombing in IPF. Pulmonary function tests reveal a restrictive pattern with reduced diffusion capacity. In certain cases, a lung biopsy may be necessary to confirm the diagnosis.
Treatment of ILDs is largely dependent on the underlying cause. For idiopathic forms, antifibrotic agents like pirfenidone and nintedanib have shown efficacy in slowing disease progression. Corticosteroids and immunosuppressants are used in ILDs associated with systemic diseases. Lung transplantation remains the only curative option for advanced disease.
ILDs are complex disorders requiring a comprehensive diagnostic approach and individualized management strategies. Continued research into their pathogenesis and treatment is crucial for improving patient outcomes. It is important for healthcare professionals to stay updated on the latest advancements in this field.
1.
Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?
2.
The need for more Latinx participants in Alzheimer's trials is urgent.
3.
Admissions, medical colleges, fees, and eligibility requirements information for the DNB Post Diploma in Radiation Oncology.
4.
Study identifies new approach to protect the brain during radiation therapy
5.
Study Supports Lactated Ringer Solution for Fluid Resuscitation in SCD
1.
CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review
2.
Treating Oral Fibromas: Options and Guidelines for a Healthier Mouth
3.
The Genetics of Bernard Soulier Syndrome: What We Know so Far
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
Unlocking The Power Of Cangrelor To Treat Heart Disease
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
2.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
3.
Navigating the Complexities of Ph Negative ALL - Part XV
4.
Lung Cancer: Risk Factors and Prevention
5.
Thromboprophylaxis In Medical Settings
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation